N4 PHARMA PLC — Major Shareholding Notification 2017

Jun 6, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Change to notifiable interest following share issue
3. Full name of person(s) subject to the notification obligation: iii		Novo A/S
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		19 May 2017
6. Date on which issuer notified:		5 June 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		Downward crossing of 12% threshold

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE		Situation previous to the triggering transaction					Resulting situation after the triggering transaction
Number of Shares		Number of Voting Rights			Number of shares		Number of voting rights
Direct		Direct xi	Indirect xii		Direct
Ordinary Shares (5p)   GB00B06GSH43		6,464,065		6,464,065			6,464,065
ADSs   US9250501064		5,925,920		5,925,920			5,925,920
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price			Expiration date xvii		Exercise/ Conversion period xviii
Total (A+B+C)
Number of voting rights
12,389,985

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
** 13. Additional information:**
14. Contact name:	Heather Ludvigsen
15. Contact telephone number:	+45 3527 6576

---

*This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via Globenewswire*